Semaglutide Linked to NAION Risk - Summary - MDSpire

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Objective:

To evaluate the long-term risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with diabetes receiving semaglutide compared to those on non-GLP-1 RA antidiabetic medications.

Key Findings:
  • Semaglutide use was not associated with a statistically significant increase in NAION risk through 1 year of follow-up.
  • Elevated relative risk of NAION emerged at 2 years and persisted through 4 years.
  • NAION occurred in 45 semaglutide-treated patients (0.026%) compared to 29 patients on non-GLP-1 RA therapies (0.017%).
  • Hazard ratio for NAION with semaglutide was 2.22 compared to non-GLP-1 RA use, indicating approximately twice the risk.
  • Increased risk observed in patients aged 40-64, female patients, White patients, and those with hypertension.
Interpretation:

The study suggests an elevated risk of NAION associated with semaglutide use in diabetic patients, particularly in specific subgroups, but findings are preliminary and require further investigation through well-designed studies.

Limitations:
  • Retrospective observational design limits causal inference.
  • Inability to verify medication adherence and potential residual confounding.
  • ICD-10 diagnostic code for NAION may not be fully specific, risking outcome misclassification.
  • Small event counts in subgroup analyses limit the robustness of findings.
Conclusion:

The study indicates an association between semaglutide use and increased NAION risk in diabetic patients, warranting further observational studies to confirm these findings.

Original Source(s)

Semaglutide Linked to NAION Risk

  • by Andrea Surnit

  • May 11, 2026

Related Content

AI Tool May Cut Macular Edema Referrals

An artificial intelligence–based optical coherence tomography pathway met noninferiority criteria for false-positive diabetic macular edema referrals and was associated with fewer referral decisions in a randomized clinical trial.

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

At Retina World Congress, Patricio G. Schlottmann, MD, discussed investigational widefield OCTA platforms made by Chinese company TowardPi Medical.

Oculomics: Beyond the Buzzword

Joseph J. Pizzimenti, OD, FAAO, FORS, discusses the capabilities of oculomics in retina and neuro-ophthalmology,